GSK's Avandia Marketing Was Racketeering, 3rd Circ. Told
Union health and welfare funds claiming they overpaid for GlaxoSmithKline LLC's diabetes drug Avandia because the company shielded the drug's heart risks urged the Third Circuit to revive their lawsuit, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article